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Dupuytren’s contracture (DC) is a benign fibroproliferative disease of the hand 
causing fibrotic nodules and fascial cords which determine debilitating 
contracture and deformities of fingers and hands. The present study was 
designed to characterize pro-inflammatory cytokines and growth factors 
involved in the pathogenesis, progression and recurrence of this disease, in 
order to find novel targets for alternative therapies and strategies in controlling 
DC. The expression of pro-inflammatory cytokines and of growth factors was 
detected by immunohistochemistry in fibrotic nodules and normal palmar fascia 
resected respectively from patients affected by Dupuytren's contracture and 
Carpal Tunnel Syndrome (as negative controls). RT-PCR analysis and 
immunofluorescence were performed to quantify the expression of TGF-β1, IL-
1β and VEGFa by primary cultures of myofibroblasts and fibroblasts isolated 
from Dupuytren's nodules. Histological analysis showed high cellularity and high 
proliferation rate in Dupuytren’s tissue, together to the presence of 
myofibroblastic isotypes; immunohistochemical staining for macrophages was 
completely negative. In addition,  a strong expression of TGF-β1, IL-1β and 
VEGFa was evident in the extracellular matrix and in the cytoplasm of 
fibroblasts and myofibroblasts in Dupuytren’s nodular tissues, as compared to 
control tissues..These results were confirmed by RT-PCR and by 
immunofluorescence in pathological and normal primary cell cultures. These 
preliminary observations suggest that TGF-β1, IL-1β and VEGFa may be 





Dupuytren’s disease (DD) has been defined as a benign progressive 
proliferative fibroplasia of the fascia palmaris of the hand, which results in 




extend them [1]. The pathogenesis of DD still remains unclear; the stages of 
the fibrotic disease are classified as proliferative, involutional, and residual on 
the basis of the histological appearance of the affected fascia palmaris [2]. The 
proliferative phase is characterized by proliferation and differentiation of 
fibroblasts into myofibroblasts under the influence of several different factors, 
causing formation of the nodules [3, 4]. In the second phase, the involutional 
stage, myofibroblasts proliferate and align along the long axis of surrounding 
collagens bundles thus giving way to the formation of fibrotic cords [5]. Finally, 
in the residual phase, the myofibroblasts are replaced by fibrocytes that 
progressively decrease in number causing the formation of the avascular 
collagen cord [2]. Myofibroblasts seem to play a central role in the 
pathogenesis of the fibrotic disease. These cells show an intermediate 
phenotype between fibroblasts and smooth muscle cells and generate the 
forces responsible for palmar fascia contracture [6]. Myofibroblasts are 
responsible for matrix deposition and consequent contraction in Dupuytren’s 
disease. Many growth factors and cytokines seem to be implicated in the 
etiology of Dupuytren’s contracture, among all transforming growth factor beta 
(TGF-β) has been suggested to play a predominant role [7]. TGF-β is 
responsible for the up-regulation of collagens and also of other extracellular 
matrix components, all fundamental for connective tissue remodeling [8]. TGF-
β transduces a signal through an heteromeric complex for formation of related 
type I and type II transmembrane serine/threonine kinase receptors [9]; the 
signal of the activated type I receptor induces SMAD signaling cascade and the 
heteromeric SMAD complexes (SMAD2/3-SMAD4) accumulated in the nucleus 
regulate the expression of a large array of target genes involved in 
myofibroblast proliferation, differentiation and extracellular matrix synthesis 
[10-11]. Several studies have identified pro-inflammatory cytokines in 
Dupuytren’s tissues, but the molecular mechanisms by which inflammatory 
mediators activate myofibroblast differentiation are still unknown [12]. Il-6 is 
involved in the modulation of TGF-β and its receptor TGF-βRII, inducing then 
fibroblasts proliferation [13]. TNF-α is another central mediator of the fibrotic 




the differentiation of fibroblasts into myofibroblasts in the palm of patients 
affected by Dupuytren’s disease, via activation of Wnt signaling pathway [15]. 
TNF-α may directly regulate TGF-β1 expression, as shown in lung fibroblasts 
[16]. Yet, hypoxia and subsequent angiogenesis seem to play a role in the 
pathophysiology of this disease [17]. Angiogenesis is induced by several growth 
factors, but the most important molecule is vascular endothelial growth factor 
(VEGF), also known as vascular permeability factor [18]. Hypoxia activates the 
transcription of hypoxia-inducible factor alpha (HIF-1α), which itself positively 
regulates VEGF synthesis  [19]. All these findings prompted us to investigate 
the structural alterations of the fibromatous palmar fascia in patients affected 
by Dupuytren’s contracture and to analyze expression and localization of  the 
previously described growth factors in surgical samples of palmar aponeurosis. 
In parallel, immunofluorescence and RT-PCR analysis were conducted on 
primary cultures of fibroblasts and myofibroblasts explanted from Dupuytren’s 
nodules in the proliferative or involutional phases.  
 
Materials and Methods 
 
Tissue samples were obtained from 26 patients (22 males and 4 females, mean 
age 58 years, mean duration of clinical history 2,5 years) undergoing surgical 
dermo-fasciectomy for Dupuytren’s contracture (n=18) and Carpal Tunnel 
Syndrome (n=8, as negative controls). Pathological tissues were sampled from 
areas of Dupuytren's nodules (4 specimens for each nodule). Control samples 
(2 specimens for each tissue fragment), characterized by normal palmar fascia 
tissues, were collected from patients undergoing hand surgery for Carpal 
Tunnel Syndrome (CTS). During excision, apart from anesthesia, no other 
chemical products or pharmaceutical drugs have been administered. All samples 
were collected with the informed consent of the patient and the study protocol 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki. 
Experiments were performed in compliance with the Italian laws and guidelines 
concerning the patients’ written informed consent. The Ethics Committee of the 




Community and Italian laws. 
Samples (72 from DD and 16 from control patients) were fixed in formalin and 
embedded in paraffin to be processed for histological staining and 
immunohistochemistry. The sections were subjected to Hematoxylin & Eosin 
and Masson’s Trichrome staining. In parallel, other tissue samples were used to 
obtain primary cultures of pathological and normal fibroblasts. 
 
Immunohistochemistry 
The immunohistochemical analysis was conducted using the ABC/HRP 
technique (avidin complexed with biotinylated peroxidase) on 4 µm thick 
paraffin sections that were cut using a rotative microtome. These sections were 
deparaffinized and hydrated through decreasing ethanol series to distilled 
water, then subjected to microwave irradiation and immersed in citrate buffer 
(pH = 6) twice for 5 minutes each time. Subsequently, endogenous peroxidase 
activity was quenched using 0.3% hydrogenous peroxide in methanol for 30 
minutes. To evaluate the immunolocalization of pro-inflammatory factors, VEGF, 
marker of myofibroblasts and proliferating cell nuclear antigen (PNCA), the 
following antibodies were employed: mouse anti-αSMA monoclonal antibody 
(Leica, USA 1:100); rabbit anti-TGF-β1 polyclonal antibody (Santa Cruz, CA, 
USA 1:200); rabbit anti-IL1β polyclonal antibody (Santa Cruz, CA, USA 1:100); 
rabbit anti-IL6 polyclonal antibody (Santa Cruz, CA, USA 1:50); mouse anti-
VEGFa monoclonal antibody (Santa Cruz, CA, USA 1:100); mouse anti-TNF-
alpha monoclonal antibody (Santa Cruz, CA, USA 1:200); mouse anti-ICAM-1 
monoclonal antibody (Santa Cruz, CA, USA 1:25) and mouse anti-PNCA 
monoclonal antibody (Santa Cruz, CA. USA 1:100). 
Incubation with the primary antibodies was performed overnight at 4ºC. 
Optimal antibody dilution and incubation times were assessed in preliminary 
experiments. As negative control, the primary antibodies were omitted. After 
exposure to the primary antibodies all slides were rinsed twice in phosphate 
buffer (pH=7.4) and incubated for 1 hour with the appropriate secondary 
biotinylated antibody at the final dilution of 1:200. The secondary biotinylated 




Abcam (biotinylated goat anti-mouse antibody and biotinylated goat anti-rabbit 
antibody). The slides were then incubated with peroxidase-conjugated avidin 
(Vector laboratories, Burlingame, CA, USA, Vectastain Elite ABC kit Standard*PK 
6-100) for 30 min. Slides were washed in phosphate buffer (pH=7.4) and 
treated with 0.05% 3,3-diaminobenzidine (DAB) and 0.1% H2O2. Finally, 
sections were counterstained with Mayer’s hematoxylin and dehydrated rapidly. 
The staining assessment was made by three experts. The intensity of the 
immune reaction was assessed microdensitometrically using an IAS 2000 image 
analyzer (Delta Sistemi, Rome, Italy) connected via a TV camera to the 
microscope. Twelve 100 µm2 areas were delineated in each section by 
measuring the diaphragm. The system was calibrated taking the background 
obtained in sections exposed to non-immune serum as zero. Quantitative data 
of the intensity of immune staining were analyzed statistically by analysis of 
variance (ANOVA) followed by Dunca’s multiple range test as a post hoc test. 
The comparison of the expression levels of each antigen between the palmar 
fascia from Dupuytren’s disease and CTS patients was carried out by Student’s 
t-test. Statistical analysis was performed using the GraphPad Prism (La Jolla, 
CA). The results were considered statistically significant with p-value <0.05.  
 
Cells Cultures 
Dupuytren’s nodule tissues and normal palmar fascia tissues from CTS patients 
were obtained by surgery. All samples were minced using a sterile technique 
and placed in sterile 30 mm single well culture dishes. The wells were then 
flooded with 2.0 ml of Dulbecco’s essential medium (DMEM, Gibco, Grand 
Island, NY) containing 4% penicillin/streptomycin (PS, Gibco, Grand Island, NY) 
and 10% fetal bovine serum (FBS, Gibco, Grand island, NY). The media was 
renewed three times weekly. Cells were observed adhering to the bottom of the 
wells and were allowed to grow to confluence. The cells were lifted from the 
wells using Trypsin/EDTA, pelleted, washed and re-suspended in DMEM with 
10% FBS and 4% penicillin/streptomycin. Four cell strains were used in these 
experiments (4 from DD patients and 4 from control patients) and sub-cultured 




cells were used for establishing protein and mRNA expression of specific pro-
inflammatory factors and VEGF by immunofluorescence and RT-PCR. 
 
Immunofluorescence 
For immunofluorescence fibroblast primary cultures were grown directly on 
Labteck chamber slides (Nunc) for at least 24 h, the cells were then washed 
with PBS with Ca/Mg, and fixed with 4 % buffered paraformaldehyde for 20 min 
at 4 °C. Fixed cells were incubated overnight at 4°C with the primary antibody 
for α-SMA, TGFβ1, IL1β, IL6, TNF-α  and VEGFa. After three washes in 0.1% 
Tween in PBS for 10 min each, the cells were incubated with the secondary 
antibody, anti-mouse-fluorescein antibody (Abcam USA (MA) 1:200) or anti-
rabbit– rhodamine antibody (Abcam USA (MA), 1:200) for 2 hours at room 
temperature. The nuclei were stained with DAPI (Vectashield Mounting Medium 
with DAPI, Vector Laboratories, Burlingame, CA, USA). The 
immunofluorescence was examined by confocal laser microscope (Nikon 
TE2000). Student’s t-test was used to evaluate  the expression of each 
analyzed antigen in DD and control cells. The data were considered statistically 
significant with p-value <0.05. 
 
RT-PCR 
Cultured cells were suspended in TRIzol reagent (Invitrogen Corporation, CA) 
and total RNA was isolated using RNeasy Micro Kit (Qiagen, CA, USA). Real time 
PCR was conducted to determine the differences in mRNA expression levels of 
TGF-β1, IL-1β and VEGFa between normal and pathological fibroblasts in 
culture. The purity of the RNA was assessed using a UV/visible spectophotomer 
(SmartSpec 3000, Bio-Rad Laboratories, CA, USA). 1 µg total RNA was reverse 
transcribed using a High Capacity cDNA Reverse Transcription (RT) kit (Applied 
Byosystems, CA, USA) according to the manufacturer’s instructions. RNA 
samples, RT buffer, dNTP mix, RT random primers, multiscribe reverse 
transcriptase, RNase inhibitor and DEPC-treated distilled water were added in 
RNase-free tubes on ice at the final volume of 20 µl. The thermal cycler was 




was stopped at 85ºC for 5 min. For the RNA reactions we used the follow 
primer pairs (Bio Basic In, NY, USA): for TGF-β1 primer forward 5’-
GCTGGACAGGAAGCTGGG-3 and primer reverse 5’-GGACACAACACGAGCAGAGA-
3’, for IL-1β primer forward 5’-GCTTCTGGTGATTCCCGCAA-3’ and primer 
reverse 5’- GGGCTGTGAGAGTTCTTGGG-3’, for VEGFa primer forward 5’-
AACCCCTAGGCCAGGTTGTA-3’ and primer reverse 5’-
CGGGATATGGAAGGGAAGCC-3. For glyceraldehyde 3 phosphate dehydrogenase 
(GAPDH) we used primer forward 5’-GAGCAGTCCGGTGTCACTAC-3' and primer 
reverse 5’-TAGTAGCCGGGCCCTACTTT-3’. The specificity of the primers was 
verified by searching in the NCBI database for possible homology to the cDNA 
of unrelated proteins. Each PCR tube contained the following reagents at the 
final volume of 50 µl: 0.2 µM of forward and reverse primers, 1 µg template 
cDNA, 0.2 mM dNTP mix, 2.5 U RedTaq Genomic DNA polymerase (Sigma-
Aldrich), MgCl2 and reaction buffer 1X. The amplification was started with an 
initial denaturation step at 94°C (2 minutes) and was followed by 35 cycles 
consisting of denaturation (30 seconds) at 94°C, annealing (30 seconds) at the 
appropriate temperature for each primer pair and extension at 72 °C (1 
minute). Using the comparative critical cycle methods, the expression levels of 
the target genes were normalized to the GAPDH endogenous control. Data 
were analyzed using the 7900 HT SDS software version 2.1 provided by applied 
Biosystems. Statistical analysis was performed using Student’s t-test (GraphPad 
Prism). The results were considered statistically significant when the p-value 
was <0.05.  
On the basis of these experiments we observed that TGF-β1 mRNA expression 
was the most significant among the examined molecules, so we performed Real 
Time PCR on paraffinized tissue in order to confirm mRNA expression data 
obtained from cell cultures. For this last procedure we used the same number 
of specimens as before (4 from DD patients and 4 from control patients). Real 
Time PCR was performed with the same protocol employed in previously 








The rate of cell proliferation was first evaluated in Dupuytren’s tissues, by 
analyzing the cellular proliferation marker known as Proliferating Cell Nuclear 
Antigen (PCNA). Fibroblasts and myofibroblasts of Dupuytren's nodules had a 
strong nuclear staining of PCNA (Fig. 1A), in contrast with the normal palmar 
fascia tissue, in which cell staining was completely absent (Fig. 1B). We 
quantified the number of positive cells on the total number of cells in 10 
different areas for each experimental group and we expressed the ratio 
between PCNA-positive cells and total cells as percentages (Fig 1C). The 
incidence of PCNA-positive nuclei in the fibromatosis nodules (87,65 % ± 4,98 
%) was significantly (P<0.0001) higher than that in the normal palmar fascia 
tissues (18,43 % ± 7,15 %). Our data demonstrate that these pathological 
samples are in the same proliferative stage of the disease that causes 
thickening and contracture of the palmar fascia. CD68 immunostaining was 
performed and it was completely negative in Dupuytren's nodules (Fig 2A) 
similarly to normal tissues (Fig. 2B), thus confirming the absence of 
macrophages and monocytes in the proliferative phase of the disease. Spindle-
shaped cells in Dupuytren's nodule resulted alpha-SMA-positive (Fig. 2C), this is 
a reliable marker of the myofibroblastic phenotype; α-SMA staining was weak or 
absent in the control tissues (Fig. 2D). The α-SMA high expression in 
Dupuytren’s tissues confirmed the trans-differentiation from fibroblasts to 
contractile myofibroblastic phenotype.  
Then TGF-β1 was highly expressed in the extracellular matrix and by fibroblasts 
and myofibroblasts of Dupuytren’s proliferative nodules (Fig. 3A); at the same 
time, a weak expression of TGF-β1 was evidenced in the fibroblasts and 
vascular endothelial cells of normal tissues, while it was completely negative in 
the extracellular matrix of normal palmar fascia (Fig. 3B). IL-1β was then 
evaluated, showing positive immunoreaction in the cytoplasm of fibroblasts and 
myofibroblasts, extracellular matrix and vascular endothelial cells of the fibro-




absent in the extracellular matrix of control samples, but weakly present in the 
cytoplasm of capillary endothelial cells and fibroblasts (Fig. 3D).  
Il-6 was strongly expressed in the extracellular matrix in its soluble form, and 
moderately present in the proliferative myofibroblasts and fibroblasts of the 
Dupuytren’s nodules (Fig. 3E). In the controls, IL-6 was completely absent at 
level of the loose connective tissue but moderately expressed in the vascular 
endothelial cells and in the fibroblasts (Fig. 3F), confirming that this cytokine is 
involved in the inflammatory process that activate the fibrotic process of 
Dupuytren’s disease.  
TNF-α was then analyzed and it resulted moderately positive in the extracellular 
matrix, fibroblasts and vascular endothelial cells of the Dupuytren’s proliferative 
site (Fig. 4A) similarly to the control tissue (Fig. 4B). Finally, VEGFa was 
strongly positive in vascular endothelium, fibroblasts and myofibroblasts of 
Dupuytren’s nodules (Fig. 4C); differently, VEGF-a was completely absent in the 
control tissues (Fig.4D). All these data were supported by immunofluorescence 
of the cultured fibroblasts and myofibroblasts isolated from Dupuytren’s 
nodules, in which α-SMA was expressed by 50% of the cells, with uniform 
cytoplasmic distribution (Fig. 5A), confirming the presence of myofibroblasts; 
while α-SMA was completely absent in the cells isolated from normal palmar 
fascia (Fig. 5B). Pathological cultured fibroblasts and myofibroblasts were also 
strongly positive for TGF-β1 expression, as compared to normal fibroblasts, 
showing a granular cytoplasmic distribution (Fig. 5 C-D). Also IL-1beta was 
strongly present in Dupuytren's cell cultures (Fig. 5E), but weakly present in 
normal fibroblasts. Finally, IL-6 was weak and moderately present in 
pathological (Fig. 5G) and normal (Fig. 5H) cultured cells. TNF alpha was 
moderately expressed by pathological cells (fig 6A), similarly to control 
fibroblasts (fig 6B). VEGFa was found to be strongly expressed in the cytoplasm 
of fibroblasts and myofibroblasts isolated from Dupuytren's tissue (fig 6C), 
while was totally absent in normal fibroblasts (Fig 6D). Our study confirmed 
that there was no difference in the intensity of the expression of this pro-
inflammatory cytokine and in the percentage of TNF-α-positive cells between 




of IL-6-positive cells between the pathological and the normal cell lines of 
fibroblasts was significant for p<0.05 (Fig. 7). On the basis of the 
immunohistochemical and immunofluorescence results that showed a stronger 
expression of TGF-β, IL-1β and VEGFa in pathological tissue, respect to normal 
tissues, we then quantified their differences in mRNA expression between 
normal and pathological tissues by RT-PCR (Fig. 8). An upregulation of  TGF-β1 
(2.30 ± 0.05), IL-1β (2.02 ± 0.07) and VEGFa (1.97 ± 0.04) was demonstrated 
in fibroblasts  from Dupuytren’s nodules compared to normal fibroblasts (Fig. 
9A). RT-PCR data were demonstrated either on cultured cells or in de-




Dupuytren’s disease is a condition in which the formation of nodules in the palm 
of the hand precedes eventual contracture of the fingers due to fibrosis [20]. 
Clusters of macrophages and T-lymphocytes have been observed, in addition to 
myofibroblasts, in the pathological tissue [6, 21-24]. Several growth factors and 
inflammatory cytokines have been reported in the literature as molecules 
probably involved in the modulation of the pathogenesis of Dupuytren’s disease 
[25-27]. TGF-β is undoubtedly one of the cytokines most involved in the 
process of fibrosis and is present at high amounts in sites of chronic 
inflammation [28-32]. Moreover, some studies have also demonstrated in vitro 
that cultured Dupuytren’s cells produce TGF-β and that TGF-β stimulates the 
growth of Dupuytren’s fibroblasts [33]. As demonstrated by Kulkarni and 
Karlsson [34] TGF-β plays other important roles in the modulation of fibrosis 
and inflammation. Our data confirm that TGF beta is more strongly present in 
DD extracellular matrix and cells, than in the correspondent normal tissue and 
cells. A new finding, not described in the previous available literature on this 
topic, is the presence of a cytoplasmic granular fluorescent staining for TGF-β1, 
whose characteristic appearance represents an interesting typical finding 
observed in DD myofibroblasts. A recent study performed by Iqbal et al. [35] 




introducing the possibility of alternative sources of DD myofibroblasts 
originating from skin overlying nodule (SON) and perinodular fat (PNF). Verjee 
et al. [15] have recently identified another possible therapeutic target in the 
TNF, whose role may be hopefully relevant in the better future knowledge of 
pathogenesis and therapy of DD. Nowadays, there are different therapeutic 
options for the treatment of DD [36], but the real question remains still: what is 
the primary cause in its pathogenesis? An important recent study [37] 
postulates diverse origins of the myofibroblasts responsible for kidney fibrosis. 
Notwithstanding the differences in comparison with DD a possible general 
“common control” of the mechanisms of fibrosis may be activated even in 
different areas of the body in response to appropriate stimuli. This “common 
control” has to be elucidated in further studies, but it probably constitutes the 
central problem in DD and in other fibrosis-related pathologies. Some authors 
recently underline the possible role of Wnt signaling [38] in the pathogenesis of 
DD, but this study implicates even nine different loci involved in genetic 
susceptibility to Dupuytren's disease. The fact that six of these nine loci harbor 
genes encoding proteins in the Wnt-signaling pathway suggests that 
aberrations in this pathway may be key to the process of fibromatosis in 
Dupuytren's disease. However further genome studies should be performed in 
order to elucidate this interesting hypothesis.  
Our results demonstrated that TGF-β, IL-1β and VEGFa are markedly expressed 
in Dupuytren’s tissue and cultured myofibroblasts. This finding led us to 
postulate a pivotal role for these molecules in the development of Dupuytren’s 
contracture. The obtained informations may provide a basis for the research of 
non-surgical treatment regimens to reduce the recurrence and the progression 
of this disease, ultimately attenuating hospitalization and post-surgical 
rehabilitation for patients.  
 
Acknowledgments  
This work was supported by a grant of the “Enrico ed Enrica Sovena” 
Foundation, Italy. The authors are grateful to Mrs. Sharon Hobby for her kind 







1. Calandruccio, J.H. (1998) Dupuytren contracture. S. Terry Canale (Ed.) 
Campbell’s Operative Orthopaedic. ninth ed. Mosby, pp. 4274-4276, St. Louis, 
MN, USA.  
2. Luck JV. (1959) Dupuytren's contracture: a new concept of the pathogenesis 
correlated with surgical management. J Bone Joint Surg Am .41, 635-664. 
3. Desai SS, Hentz VR. (2011) The treatment of Dupuytren disease. J Hand 
Surg Am. 36, 936-42. 
4. Shih B, Bayat A. (2010) Scientific understanding and clinical management of 
Dupuytren disease. Nat Rev Rheumatol. 6, 715-726. 
5. Schurch W, Skali I, Gabbiania G. Cellular biology. (1990) McFarlane RM, 
McGrouther DA, Flint MH, eds. Dupuytren’s Disease, pp. 31-4, New York: 
Churchill Livingstone. 
6. Gabbiani G, Majno G. (1972) Dupuytren’s contracture: fibroblast contraction? 
An ultrastructural  study. Am J Pathol. 66, 131-138. 
7. Kloen P. (1999) New insights in the development of Dupuytren’s contracture: 
a review. Br J Plast Surg. 52, 629-635. 
8. Badalamenti MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K. (1996) The 
role of TGF-beta in Dupuytren’s disease. J Hand Surg. 21A, 210-215. 
9. Heldin CH, Miyazono K, Ten Dijke P. (1997) TGF-beta signaling from cell 
membrane to nucleus through SMAD proteins. Nature. 390, 465-471. 
10. Schmierer B, Hill CS. (2007) TGFβ-SMAD signal transduction: molecular 
specificity and functional flexibility. Nat Rev Mol Cell Biol. 8, 970-982. 
11. Tomasek JJ, Gabbiani  G, Hinz B, Chaponnier C, Brown RA. (2002) 
Myofibroblasts and mechano-regulation of connective tissue remodeling. Nat 
Rev Mol Cell Biol. 3, 349-363. 
12. AndrewJG, Andrew SM, Ash A, Turner B (1991). An investigation into the 
role of inflammatory cells in Dupuytren’s disease. J Hand Surg (Br). 16, 267-271 





14. Sanchez-Muñoz F, Dominguez-lopez A, Yamamoto-Furusho JK. (2008) Role 
of cytokines in inflammatory bowel disease. World J Gastroenterol. 14, 4280-
4288. 
15. LS Verjee, JSN Verhoekx, JKK Chan, T Krausgruber, V Nicolaidou, D Izadi, D 
Davison, M Feldmann, KS Midwood, and J Nanchahal. (2013) Unraveling the 
signaling pathway promoting fibrosis in Dupuytren’s disease  revels TNF as a 
therapeutic targer. PNAS; 110, 928-937. 
16. Sullivan DE, Ferris M,Pociask D, Brody AR. (2005) Tumor necrosis factor-
alpha induces transforming growth factor-beta 1expression in lung fibroblasts 
through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol 
Biol. 32, 342-349. 
17. LA Holzer, A Cor, G Pfandlsteiner, G Holzer. (2013) Expression of VEGF, its 
receptors, and HIF-1a in Dupuytren disease. Acta Orthopaedica. 84, 420-425. 
18. Tischer E, Michell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, 
Abraham JA. (1991) The human gene for vascular endothelial growth factor. 
Multiple protein forms are encoded through alternative exon splicing. J Biol 
Chem. 266, 11947-54. 
19. Ke Q, Costa M. (2006) Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 
70, 1469-1480. 
20. Meek R M  , McLellan S, Crossan J F. (1999) Dupuytren’s disease: a model 
for the mechanism of fibrosis and its modulation by steroids. Bone and Joint 
Surgery. 81, 732-738. 
21. Iwasaki H, Muller H, Stutte HJ, Brennscheidt U. (1984) Palmar fibromatosis 
(Dupuytren’s contracture): ultrastructural and enzyme histochemical studies of 
43 cases. Virch Arch A. 405, 41-53. 
22. Scurch W, Seemayer TA, Gabbiani G. (1992) Myofibroblast. In: Sternberg 
SS, ed. Histology for pathologists. New York, Raven Press. pp. 118-25.  
23. Azzarone B, Failly-Crepin C, Daya-Grosjean L, Chaponnier C, Gabbiani G 
(1983) Abnormal behaviour of cultured fibroblasts from nodule and non-
affected aponeurosis of Dupuytren’s disease. J Cell Physiol. 117, 353-61. 
24. Baird KS, Alwan WH, Crossan JF, Wojciak B. (1993) T-cell mediated 




25. Baird KS, Crossan JF, Ralston SH. (1993) Abnormal growth factor and 
cytokine expression in Dupuytren’s contracture. J Clin Pathol. 46, 425-8. 
26. Meek RMD, Wojciak B, Crossan JF. (1996) Dupuytren’s fibroblasts secrete 
interleukin-8, a powerful lymphocyte chemoattractant. British Society for 
Surgery of the Hand Birmingham.  
27. Baird KS. (1994) Aetiopathogenesis of Dupuytren’s contracture. Rheumatol 
Rev. 3, 111-23. 
28. Roberts AB, Sporn MB, Assoain RK, et al. (1986) Transforming growth 
factor type beta: rapid induction of fibrosis and angiogenesis in vivo and 
stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 83, 4167-71. 
29. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. (1987) 
Transforming growth factor-beta increases steady state levels of type I 
procollagen and fibronectin messenger RNAs posttranscriptionally incultured 
human dermal fibroblasts. J Clin Invest. 79, 1285-8. 
30. Massague J, Heino J, Laiho M. (1991) Mechanisms in TGF-beta action. Ciba 
Found Sym, 157, 51-9. 
31 Ignotz RA, Massague J. (1986) Transforming growth factor beta stimulates 
the expression of fibronectin and collagen and their incorporation into the 
extracellular matrix. J Biol Chem. 261, 4337-45. 
32. Wahl SM, Costa GL, Mizel DE, et al. (1993) Role of transforming growth 
factor beta in the pathophysiology of chronic inflammation. J Peridontol. 64, 
450-5. 
33. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. (1995) 
Transforming growth factor-beta: possible roles in Dupuytren’s contracture. J 
Hand Surg Am. 20, 101-8. 
34. Kulkarni AB, Karlsson S. (1993) Transforming growth factor-beta knockout 
mice: a mutation in one cytokine gene causes a dramatic inflammatory disease. 
Am J Pathol. 143, 3-9. 
35. Iqbal SA, Manning C, Syed F, Kolluru V, Hayton M, Watson S, Bayat A. 
(2012) Identification of mesenchymal stem cells in perinodular fat and skin in 
Dupuytren’s disease: a potential source of myofibroblasts with implications for 




36. Eaton C. (2014) Evidence-based medicine: Dupuytren contracture. Plast 
Reconstr Surg. 133, 1241-51.  
37. Falke LL, Gholizadeh S, Goldschmeding R, Kok RJ, Nguyen TQ. (2015) 
Diverse origins of the myofibroblasts: implications for kidney fibrosis.  Nat Rev 
Nephrol. 11, 233-44. 
38. Dolmans GH, Werker PM, Hennies HC, Furniss D, Festen EA, Franke L, 
Becker K, Van Der Vlies P, Wolffenbuttel BH, Tinschert S, Toliat MR, Nothnagel 
M, Franke A, Klopp N, Wichmann HE, Nürnberg P, Giele H, Ophoff RA, 
Wijmenga C, Dutch Dupuytren Study Group, German Dupuytren Study Group, 
the LifeLines Cohort Study, and the BSSH–GODD Consortium. (2011) Wnt 





























Figure 1. Immunohistochemical analysis of PCNA, CD68 and α-SMA markers in  
Dupuytren’s nodules and control tissues. The photomicrographs of Dupuytren’s 
nodular tissues showed an increasing number of PCNA (A) and α-SMA-positive 
cells (C) compared to the control tissues in which these markers resulted 
completely negative (D, F). Immunohistochemistry for CD-68 showed that the 
macrophages and monocytes were completely absent in the pathological nodule 















Figure 2. Cell proliferation index in Dupuytren’s nodules and normal fascia 
palmar tissues. PCNA proliferative index  is represented as a percentage of 
PCNA-positive nuclei on the total number of cells in Dupuytren’s nodules (87.65 
% ± 4.98) and normal fascia palmar tissues (18% ± 7,15). The bar graph 
indicates the mean percentage of PCNA positive cells ± SD.  Statistical analysis 












Figure 3. Immunohistochemical analysis of pro-inflammatory markers TGF-β, 
IL-1β and IL-6 in Dupuytren’s nodules and controls. TGF-β was strongly 
expressed in the extracellular matrix and cytoplasm of proliferative 
myofibroblasts and fibroblasts in the pathological tissue (A). TGF-β was 
moderately present in the cytoplasm of fibroblasts scattered in the loose 
connective tissue of normal fascia palmar (D).  Il-1β was strongly positive in 
Dupuytren's myofibroblasts - rich nodules showing cytoplasmic localization (B).  
IL-1beta was completely absent in the extracellular matrix and weakly present 
in the vascular endothelium and fibroblasts of normal palmar fascia (E). IL-6 
was moderately expressed in the extracellular matrix and fibroblasts of 











Figure 4. Immunohistochemical analysis of TNF-α and VEGF in Dupuytren’s 
nodules and control tissues. A moderate expression of TNF-α is seen in the 
extracellular matrix and fibroblasts of Dupuytren’s nodules (A) and control 
tissues (C) (magnification 40X). VEGF immunoreactivity appears to be strongly 
positive in the extracellular matrix, fibroblasts and  myofibroblasts of 
Dupuytren’s nodules (B) (magnification 40X). compared to controls in which the 
staining was completely absent in the amorphous substance and weakly 








Figure 5. Immunofluorescence for α-SMA and pro-inflammatory factors TGF-β, 
IL-β, IL-6 in fibroblast cultures isolated from Dupuytren’s nodules and normal 
palmar fascia. The pathological fibroblasts isolated from Dupuytren’s nodules 
(A) showed a strong expression of α-SMA demonstrating that 50% of 
fibroblasts differ in myofibroblasts. In the normal fibroblasts, α-SMA expression 
was completely absent (E). TGF-β and IL-β were strongly expressed in the 
pathological fibroblasts isolated from Dupuytren’s tissues (B, C,) compared to 
the normal fibroblasts (F, G,) that showed a weak expression of these pro-
inflammatory factors. IL-6 was moderately expressed in the cytoplasm of 








Figure 6. Immunofluorescence for TNF-α and VEGF in fibroblast cells isolated 
from Dupuytren’s nodules and normal palmar fascia. TNF-α was moderately 
expressed in the pathological fibroblast cultures (A) similarly to the control 
fibroblasts (C).A strong VEGF expression was found in the cytoplasm of 
Dupuytren’s fibroblasts (B) differently from fibroblasts isolated from normal 










Figure 7. Pro-inflammatory cytokines and VEGF positive cell index in the 
fibroblasts isolated from Dupuytren's contracture and normal palmar fascia 
tissue. The bar graph indicates the mean % growth factors-positive cells ± SD. 







Figure 8. Quantitative PCR analysis in Dupuytren’s nodules-derived cells, in 
control tissue and in paraffinized tissue samples. A (upper): PCR analysis of 
mRNA expression for TGF-β1, IL-1β and VEGF-A in nodules-derived cells and in 
control normal tissue. Data are presented as mean ± SEM . Statistical analysis 
is performed using Student’s t-test. * p-value <0.05. 
B (down): PCR analysis of mRNA expression for TGF-β1 in paraffinized tissue 
samples from DD patients and control ones. 
